11月12日,来凯医药宣布:与齐鲁制药签订独家许可协议,授予其在中国地区研究、开发及商业化乳腺癌候选新药LAE002 (Afuresertib)的权益。根据协议条款,到首个适应症在中国上市为止,来凯有权获得最高5.3 亿元不可退还的首付款和临床开发里程碑付款。总的首付款及里程碑款项将达到20.45亿元。此外,来凯还有权收取梯度销售分成,分成比例在十余个百分点至二十余个百分点之间。LAE002是...
Source Link11月12日,来凯医药宣布:与齐鲁制药签订独家许可协议,授予其在中国地区研究、开发及商业化乳腺癌候选新药LAE002 (Afuresertib)的权益。根据协议条款,到首个适应症在中国上市为止,来凯有权获得最高5.3 亿元不可退还的首付款和临床开发里程碑付款。总的首付款及里程碑款项将达到20.45亿元。此外,来凯还有权收取梯度销售分成,分成比例在十余个百分点至二十余个百分点之间。LAE002是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.